27867086|t|Diazoxide prevents reactive oxygen species and mitochondrial damage, leading to anti-hypertrophic effects
27867086|a|Pathological cardiac hypertrophy is characterized by wall thickening or chamber enlargement of the heart in response to pressure or volume overload, respectively. This condition will, initially, improve the organ contractile function, but if sustained will render dysfunctional mitochondria and oxidative stress. Mitochondrial ATP-sensitive K(+) channels (mitoKATP) modulate the redox status of the cell and protect against several cardiac insults. Here, we tested the hypothesis that mitoKATP opening (using diazoxide) will avoid isoproterenol - induced cardiac hypertrophy in vivo by decreasing reactive oxygen species (ROS) production and mitochondrial Ca(2+) - induced swelling. To induce cardiac hypertrophy, Swiss mice were treated intraperitoneally with isoproterenol (30 mg/kg/ day) for 8 days. Diazoxide (5 mg/kg/ day) was used to open mitoKATP and 5-hydroxydecanoate (5 mg/kg/ day) was administrated as a mitoKATP blocker. Isoproterenol - treated mice had elevated heart weight / tibia length ratios and increased myocyte cross-sectional areas. Additionally, hypertrophic hearts produced higher levels of H2O2 and had lower glutathione peroxidase activity. In contrast, mitoKATP opening with diazoxide blocked all isoproterenol effects in a manner reversed by 5-hydroxydecanoate. Isolated mitochondria from Isoproterenol - induced hypertrophic hearts had increased susceptibility to Ca(2+) - induced swelling secondary to mitochondrial permeability transition pore opening. MitokATP opening was accompanied by lower Ca(2+) - induced mitochondrial swelling, an effect blocked by 5-hydroxydecanoate. Our results suggest that mitoKATP opening negatively regulates cardiac hypertrophy by avoiding oxidative impairment and mitochondrial damage.
27867086	0	9	Diazoxide	T109,T121	C0012022
27867086	10	18	prevents	T169	C1292733
27867086	19	42	reactive oxygen species	T123,T196	C0162772
27867086	47	67	mitochondrial damage	T046	C1096176
27867086	80	105	anti-hypertrophic effects	T033	C0243095
27867086	106	118	Pathological	T169	C0205469
27867086	119	138	cardiac hypertrophy	T046	C1383860
27867086	142	155	characterized	T052	C1880022
27867086	159	163	wall	T023	C0446987
27867086	164	174	thickening	T033	C0205400
27867086	178	185	chamber	T023	C0729936
27867086	186	197	enlargement	T046	C0020564
27867086	205	210	heart	T023	C0018787
27867086	226	234	pressure	T081	C4284008
27867086	238	244	volume	T081	C0449468
27867086	274	283	condition	T080	C0348080
27867086	301	308	improve	T033	C0184511
27867086	313	318	organ	T023	C0178784
27867086	319	339	contractile function	T042	C1258017
27867086	348	357	sustained	T169	C0443318
27867086	370	383	dysfunctional	T077	C3887504
27867086	384	396	mitochondria	T026	C0026237
27867086	401	417	oxidative stress	T049	C0242606
27867086	419	460	Mitochondrial ATP-sensitive K(+) channels	T116,T192	C0764439
27867086	462	470	mitoKATP	T116,T192	C0764439
27867086	472	480	modulate	T082	C0443264
27867086	485	497	redox status	T044	C0030012
27867086	505	509	cell	T025	C0007634
27867086	514	521	protect	T033	C1545588
27867086	538	545	cardiac	T023	C0018787
27867086	546	553	insults	T169	C1883709
27867086	575	585	hypothesis	T078	C1512571
27867086	591	599	mitoKATP	T116,T192	C0764439
27867086	600	607	opening	T082	C1882151
27867086	615	624	diazoxide	T109,T121	C0012022
27867086	637	650	isoproterenol	T109,T121	C0022245
27867086	653	660	induced	T169	C0205263
27867086	661	680	cardiac hypertrophy	T046	C1383860
27867086	681	688	in vivo	T082	C1515655
27867086	703	726	reactive oxygen species	T123,T196	C0162772
27867086	727	731	(ROS	T123,T196	C0162772
27867086	748	761	mitochondrial	T026	C0026237
27867086	762	768	Ca(2+)	T121,T196	C0596235
27867086	771	778	induced	T169	C0205263
27867086	779	787	swelling	T033	C0038999
27867086	792	798	induce	T169	C0205263
27867086	799	818	cardiac hypertrophy	T046	C1383860
27867086	820	830	Swiss mice	T015	C0162416
27867086	836	843	treated	T169	C1522326
27867086	844	861	intraperitoneally	T082	C0442120
27867086	867	880	isoproterenol	T109,T121	C0022245
27867086	892	895	day	T079	C0439228
27867086	903	907	days	T079	C0439228
27867086	909	918	Diazoxide	T109,T121	C0012022
27867086	929	932	day	T079	C0439228
27867086	951	959	mitoKATP	T116,T192	C0764439
27867086	964	982	5-hydroxydecanoate	T109,T121	C0098450
27867086	993	996	day	T079	C0439228
27867086	1021	1029	mitoKATP	T116,T192	C0764439
27867086	1030	1037	blocker	T121	C0870261
27867086	1039	1052	Isoproterenol	T109,T121	C0022245
27867086	1055	1062	treated	T169	C1522326
27867086	1063	1067	mice	T015	C0025929
27867086	1072	1080	elevated	T080	C3163633
27867086	1081	1086	heart	T023	C0018787
27867086	1087	1093	weight	T081	C0043100
27867086	1096	1101	tibia	T023	C1279118
27867086	1102	1108	length	T081	C1444754
27867086	1109	1115	ratios	T081	C0456603
27867086	1120	1129	increased	T081	C0205217
27867086	1130	1137	myocyte	T025	C0225828
27867086	1138	1159	cross-sectional areas	T033	C0243095
27867086	1175	1187	hypertrophic	T169	C0333959
27867086	1188	1194	hearts	T023	C0018787
27867086	1204	1210	higher	T080	C0205250
27867086	1211	1217	levels	T080	C0441889
27867086	1221	1225	H2O2	T121,T130,T197	C0020281
27867086	1240	1271	glutathione peroxidase activity	T044	C1151528
27867086	1286	1294	mitoKATP	T116,T192	C0764439
27867086	1295	1302	opening	T082	C1882151
27867086	1308	1317	diazoxide	T109,T121	C0012022
27867086	1318	1325	blocked	T169	C0332206
27867086	1330	1343	isoproterenol	T109,T121	C0022245
27867086	1344	1351	effects	T080	C1280500
27867086	1364	1372	reversed	T169	C1555029
27867086	1376	1394	5-hydroxydecanoate	T109,T121	C0098450
27867086	1396	1404	Isolated	T169	C0205409
27867086	1405	1417	mitochondria	T026	C0026237
27867086	1423	1436	Isoproterenol	T109,T121	C0022245
27867086	1439	1446	induced	T169	C0205263
27867086	1447	1459	hypertrophic	T169	C0333959
27867086	1460	1466	hearts	T023	C0018787
27867086	1471	1480	increased	T081	C0205217
27867086	1481	1495	susceptibility	T169	C0231204
27867086	1499	1505	Ca(2+)	T121,T196	C0596235
27867086	1508	1515	induced	T169	C0205263
27867086	1516	1524	swelling	T033	C0038999
27867086	1538	1580	mitochondrial permeability transition pore	T116,T123	C0908146
27867086	1581	1588	opening	T082	C1882151
27867086	1590	1598	MitokATP	T116,T192	C0764439
27867086	1599	1606	opening	T082	C1882151
27867086	1632	1638	Ca(2+)	T121,T196	C0596235
27867086	1641	1648	induced	T169	C0205263
27867086	1649	1671	mitochondrial swelling	T049	C0026244
27867086	1676	1682	effect	T080	C1280500
27867086	1683	1690	blocked	T169	C0332206
27867086	1694	1712	5-hydroxydecanoate	T109,T121	C0098450
27867086	1739	1747	mitoKATP	T116,T192	C0764439
27867086	1748	1755	opening	T082	C1882151
27867086	1756	1766	negatively	T033	C0205160
27867086	1767	1776	regulates	T038	C1327622
27867086	1777	1796	cardiac hypertrophy	T046	C1383860
27867086	1809	1818	oxidative	T169	C0311404
27867086	1819	1829	impairment	T169	C0221099
27867086	1834	1854	mitochondrial damage	T046	C1096176